Navigation Links
Viralytics Full Year Financial Results
Date:9/3/2013

SYDNEY, Sept. 3, 2013 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013. 

 Financial ResultsNet cash used in operating activities for the Year

$3.9 millionCash position at the end of the Year

$5.1 millionReported loss

$4.1 million 

Operational HighlightsCAVATAK™ Phase II CALM Melanoma Clinical Trial (USA) Highlights include:

  • CAVATAK™ presented at the American Society of Clinical Oncologists conference in June 2013 and the World Melanoma Congress in July 2013 to a global oncology audience.
  • Key milestone achieved with enrolment of the 35th patient. Independent Data Monitoring Committee reported that CAVATAK™ had met safety and tolerability criteria.
  • Patient enrolment now at 10 prestigious US cancer clinics, with acceleration since early 2013. Aiming for full recruitment by the end of the calendar year.
  • 23 patients have reached assessment point against the trial's primary endpoint of immune related Progression Free Survival (irPFS) at 6 months. Interim results very promising with 8 of 23 patients having achieved the primary endpoint. Trial target is 10 of 54 evaluable patients achieving primary endpoint.
  • 2 complete and 6 partial tumour responses from 30 assessable patients. Anti-cancer activity demonstrated in non-injected (metastatic or secondary) as well as the injected tumours.
  • CAVATAK™ Phase I studies completed (Australia)

  • Intravenously administered CAVATAK™ well tolerated in late stage cancer patients.
  • Some evidence of tumour stabilization in intravenous study after only a single dose.
  • Sound basis for a multi-dose intravenous Phase 1 / 2 trial (our STORM study).
  • CAVATAK™ Preclinical studies completed (A
    '/>"/>

    SOURCE Viralytics Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
    2. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
    5. EntreMed Reports Second Quarter 2013 Financial Results
    6. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
    7. Sinovac Reports Unaudited Second Quarter 2013 Financial Results
    8. Vasomedical Announces Financial Results for the Second Quarter of 2013
    9. Nephros Reports Second Quarter 2013 Financial Results
    10. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    11. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... 31, 2015 Pepperl+Fuchs, a world leader ... Corporation, a leading provider of HART protocol devices. ... further extend its integrated solutions offerings and strengthen ... "We are pleased to add the MACTek ... Jim Bolin , Pepperl+Fuchs, executive vice president ...
    (Date:8/31/2015)... Diagnostics today announced a collaboration with Merck, known as MSD ... Canada , to develop Daktari,s rapid hepatitis C ... million over the next 3.5 years, will support an accelerated ... Daktari,s HCV test. The Daktari technology forms ... levels of virus directly in a single drop of blood ...
    (Date:8/31/2015)... Aug. 31, 2015  On August 5, 2015, the ... Oregon denied motions to dismiss securities class ... ) and certain of its directors. The class actions ... and dump" scheme to artificially inflate Galena,s stock price, ... stock price was inflated, sold massive amounts of their ...
    Breaking Medicine Technology:Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2
    ... May 15, 2012  Boston Scientific Corporation (NYSE: ... trial, which evaluated the acute safety of the Lotus™ ... disease.  The Lotus Aortic Valve System is the first ... that is designed to minimize aortic regurgitation (leaking) and ...
    ... year,s Annual Scientific Meeting of the American Pain ... will present results from clinical studies utilizing a ... is designed to be crush-resistant and to protect ... to prescription opioid drugs is considered an efficient ...
    Cached Medicine Technology:Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 2Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 3Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 4Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial 5INTAC™ Technology Combats Misuse of Extended Release Drugs 2
    (Date:8/31/2015)... , ... August 31, 2015 , ... ... Urology was formed in 2008, the result of a merger of five of ... by working cooperatively, they could provide more cost-effective and higher quality care than ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic ... , At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ... the entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic ...
    (Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... conducted out of the University of Sweden showed that most adolescents who underwent bariatric ... that, on average, the 88 adolescent bariatric patients who participated in the study felt ...
    (Date:8/31/2015)... ... , ... Three Bakers Gluten Free Bakery launched the redesign of its website, ... information on their offering of gluten-free breads and pizzas, living without gluten, and resources ... us to share information about our gluten free product offerings, but also to really ...
    (Date:8/31/2015)... ... August 31, 2015 , ... ... professor Luciana Lagana (aka Dr. Luciana) received a total of three Silver ... Best Documentary, and Best (Dis)ability Film. Dr. Luciana co-wrote and co-produced this pilot ...
    Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2Health News:Actor/Writer/Director/Psychology Professor Luciana Lagana Receives Three Wins at the 2015 Global Independent Film Awards for the TV Pilot Dr. Luciana on Aging and Falling 2
    ... USDA communiqué has indicated India's stance on Poultry imports, which ... period. Poultry products, live poultry and import// of pork will ... outbreak. ,The prohibited products will include ... Avian Species including semen of domestic and wild birds. India ...
    ... toast to tea and its proven benefits to health, which ... dissecting and analyzing data// on tea consumption, researchers say with ... is capable of preventing a potential heart attack. ... presence of flavanoids, which are antioxidants known to offset cell ...
    ... two new drugs on the Pharmaceutical Benefits Scheme will ... October.// ,According to Health Minister Tony Abbott ... from October 1, at a cost of $145 million ... have several medical advantages over current subsidized treatments. ...
    ... Clinic estimates that about 5 million adult Americans have moderate ... according to a Mayo Clinic study// published online in The ... cause of valve diseases and was a major public health ... fever is not a serious concern in this country today, ...
    ... shrinking stomach and esophagus tumors in four out of 12 ... patients had at least 50 percent reduction in their tumor ... be given along with radiation, it added. The company said ... the medicine is useful. A study on the effects is ...
    ... new study finds that taking oral contraceptive pills after ... ,Researchers at the Osaka University Graduate School ... could prevent vaginal bleeding between menstrual cycles after a ... at the site of the surgery could result in ...
    Cached Medicine News:Health News:Valve Disease Study Suggests New Public Health Concern 2Health News:Valve Disease Study Suggests New Public Health Concern 3
    ... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
    Convective Air Warming Blankets...
    MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
    Inquire...
    Medicine Products: